Publication
Genomic and biological characterization of exon 4 KRAS mutations in human cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerMalignant Colorectal Neoplasmcivic_curation1.00
- cancerMalignant Neoplasmcivic_curation1.00
- drugCetuximabcivic_curation1.00
- geneKRAScivic_curation1.00
- variantKRAS A146Tcivic_curation1.00
Curated evidence
Evidence citing this paper (6)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 20570890
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| KRAS A146T3 | ||||||||
| Cetuximab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | D | Supports Resistance | 3 | accepted | EID2943Preclinical data supporting resistance of Exon 4 mutations, in particular A146T, to cetuximab and sensitivity to PD0325901. This study involved treatment of mice bearing A146T KRAS xenografts treated … (full text at CIViC) PMID 20570890 · Janakiraman et al., 2010 · Open in CIViC | civic |
| Mirdametinib | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID2944Preclinical data supporting resistance of Exon 4 mutations, in particular A146T, to cetuximab and sensitivity to PD0325901. PMID 20570890 · Janakiraman et al., 2010 · Open in CIViC | civic |
| (oncogenic) | Malignant NeoplasmALIAS | Oncogenic | D | Supports Oncogenicity | 4 | accepted | EID12947This study provides robust preclinical evidence, supported by genomic data from human tumors, demonstrating that exon 4 mutations in KRAS (particularly at codon 146) represent functionally oncogenic v… (full text at CIViC) PMID 20570890 · Janakiraman et al., 2010 · Open in CIViC | civic |
| KRAS Q61E1 | ||||||||
| Irinotecan | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Supports Resistance | — | submitted | EID2808In colorectal cancer patients, non-G12/G13 KRAS and NRAS mutations were associated with improved disease-free survival (n=186, P=0.006) compared to G12 and G13 KRAS mutations. None of the 12 Stage I-… (full text at CIViC) PMID 20570890 · Janakiraman et al., 2010 · Open in CIViC | civic |
| KRAS Q61FS1 | ||||||||
| (prognostic) | Malignant Colorectal NeoplasmCURATED_BROADER | Prognostic | B | Supports Better Outcome | 3 | submitted | EID2810In colorectal cancer patients, non-G12/G13 KRAS and NRAS mutations were associated with improved disease-free survival (n=186, P=0.006) compared to G12 and G13 KRAS mutations. None of the 12 Stage I-… (full text at CIViC) PMID 20570890 · Janakiraman et al., 2010 · Open in CIViC | civic |
| KRAS Q61P1 | ||||||||
| Irinotecan | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Supports Resistance | — | submitted | EID2806In colorectal cancer patients, non-G12/G13 KRAS and NRAS mutations were associated with improved disease-free survival (n=186, P=0.006) compared to G12 and G13 KRAS mutations. None of the 12 Stage I-… (full text at CIViC) PMID 20570890 · Janakiraman et al., 2010 · Open in CIViC | civic |